Company pays over $81m for allegedly promoting topiramate for unapproved uses.
Zosia
Z
Kmietowicz
D000927:Anticonvulsants / Q000191:economics*; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D005632:Fructose / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D040541:Marketing / Q000191:economics / Q000331:legislation & jurisprudence; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics; D056687:Off-Label Use / Q000191:economics / Q000331:legislation & jurisprudence*; D000077236:Topiramate; D014481:United States
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose